DUBLIN – Inventiva SA raised €48 million ($50.9 million) in the third European biotech IPO of 2017. The Dijon, France-based drug developer priced the offer at €8.50 per share, at the bottom of the indicative range of €8.50 to €9.75 it set at the start of the bookbuilding process.